GSP Crop Science IPO Listing: Modest Debut, Strong Post-Listing Rally to ₹ 390 (22% Gain)

By April 1, 2026, the stock had moved much higher and closed at ₹390.90. The share also touched an intraday high of ₹399.80 during the session. This means the stock closed about 22.16% above the IPO issue price and moved nearly 24.94% above the issue price at the day’s high.

The movement made GSP Crop Science an interesting post-listing case. The IPO did not open with a large listing premium, retail subscription was weak, but the stock still saw a strong move after listing. This article explains the listing price, April 1 price movement, IPO structure, subscription pattern, business profile and key risks from the prospectus.

GSP Crop Science Post-Listing Snapshot

From Listing Price to April 1: What Changed?

GSP Crop Science did not begin trading with a very high listing premium. The BSE listing price of ₹332.30 was only ₹12.30 above the issue price, while the NSE listing price of ₹328 was ₹8 above the issue price.

The stronger move came after listing. By April 1, the stock closed at ₹390.90, which was ₹70.90 higher than the IPO price. Compared with the NSE listing price of ₹328, the April 1 close was higher by ₹62.90 per share. Compared with the BSE listing price of ₹332.30, it was higher by ₹58.60 per share.

This makes the post-listing movement more important than the listing-day premium. The stock’s first public-market phase showed a muted debut followed by stronger secondary-market buying.

One-Lot Gain Calculation

The IPO lot size was 46 shares. At the issue price of ₹320, one lot cost ₹14,720. At the April 1 closing price of ₹390.90, one lot was worth ₹17,981.40.

This means one IPO lot showed a gain of ₹3,261.40 at the April 1 closing price. At the intraday high of ₹399.80, one lot was worth ₹18,390.80, showing a gain of ₹3,670.80 over the IPO application amount.

Why the Rally Stood Out

The post-listing rally stood out because the IPO did not have a very strong retail response during the bidding period. The issue was subscribed around 1.61 times overall, but the retail portion was subscribed only about 0.40 times.

Demand was stronger in the QIB and NII categories. QIB subscription was about 2.66 times, while NII subscription was about 3.05 times. This meant the IPO was supported more by institutional and non-institutional demand than by retail participation.

The price movement after listing suggests that secondary-market demand developed after the initial listing. The stock’s move from a modest listing premium to a ₹390.90 close by April 1 made the article more of a post-listing rally story than a simple IPO debut report.

IPO Structure: ₹400 Crore Fresh Issue and OFS

GSP Crop Science IPO was a ₹400 crore book-built offer. The offer consisted of a fresh issue of 75,00,000 equity shares aggregating to ₹240 crore and an offer for sale of 50,00,000 equity shares aggregating to ₹160 crore.

The offer for sale was by promoter selling shareholders Vilasben Vrajmohan Shah, Bhavesh Vrajmohan Shah and Kappa Trust. The final offer price was fixed at ₹320 per share, which was the upper end of the ₹304 to ₹320 price band.

Use of Fresh Issue Proceeds

The prospectus states that the net proceeds from the fresh issue are proposed to be used mainly for repayment or prepayment of certain outstanding borrowings and general corporate purposes.

Out of the net proceeds, ₹170 crore is proposed to be used for repayment or prepayment of all or a portion of certain outstanding borrowings. The balance amount is proposed for general corporate purposes, subject to the limits stated in the prospectus.

This gives the IPO a balance-sheet strengthening angle. The fresh issue is not mainly a new factory or capacity-expansion issue; a large part of the proceeds is linked to reducing borrowings.

Business Profile: Agrochemicals Across Formulations and Technicals

GSP Crop Science is an Ahmedabad-based agrochemical company with operations dating back to 1985. The company develops, manufactures and markets crop protection products used in agriculture.

Its product portfolio includes insecticides, herbicides, fungicides and plant growth regulators. The business operates across two major product categories: formulations and technicals.

Formulations are finished crop protection products prepared using active ingredients and additives. Technicals are concentrated active ingredients that are used to manufacture formulations. This gives the company exposure to both downstream branded products and upstream active ingredients.

Product Registrations and R&D Position

Agrochemical companies depend heavily on product registrations and regulatory approvals. As of September 30, 2025, GSP Crop Science had obtained 524 registrations from the Central Insecticides Board and Registration Committee.

These included registrations across formulations and technicals for domestic and export markets. The company also had 102 granted patents and 108 patent applications under process as of the prospectus date.

This registration and patent base is important because agrochemical product development depends on regulatory clearance, formulation capability, technical manufacturing and market access.

Revenue Mix: Formulations Remain the Larger Business

The prospectus shows that formulations are the larger part of the company’s product revenue. For Fiscal 2025, formulations contributed ₹878.92 crore, or 70.56% of sale of products from continuing operations. Technicals contributed ₹366.69 crore, or 29.44%.

For the six months ended September 30, 2025, formulations contributed ₹603.48 crore, or 71.81%, while technicals contributed ₹236.91 crore, or 28.19%.

Domestic Business and International Presence

GSP Crop Science earns most of its revenue from India. For Fiscal 2025, domestic business contributed ₹1,143.45 crore, or 88.82% of revenue from continuing operations. International business contributed ₹143.93 crore, or 11.18%.

For the six months ended September 30, 2025, domestic business contributed 90.43% of revenue from continuing operations, while international business contributed 9.57%.

The company’s international business includes markets such as Uruguay, the United States, Vietnam, Brazil, Singapore, Bangladesh, the United Arab Emirates, Taiwan, Australia and Sri Lanka. The company also acquired GSP Agroquimica Do Brasil LTDA in Brazil in 2023 to expand its presence in Latin America.

Manufacturing Footprint

As of September 30, 2025, GSP Crop Science had five manufacturing facilities. These facilities are located at Odhav and Kathwada in Ahmedabad, Nandesari in Vadodara, Saykha in Dahej and Samba in Jammu & Kashmir.

The company’s annual aggregated installed capacity stood at 15,120 MTPA for technicals, 43,672 MTPA for formulations and 5,400 MTPA for intermediates across these facilities.

This manufacturing base supports the company’s position across both technicals and formulations, but it also makes regulatory approvals, plant operations, raw material supply and environmental compliance important business factors.

Valuation at IPO Price and After the Rally

At the final issue price of ₹320 per share, the price-to-earnings ratio based on diluted EPS for Fiscal 2025 was 14.97 times. At the lower end of the price band of ₹304, the P/E ratio was 14.22 times.

After the stock moved to ₹390.90 by April 1, the valuation context changed from IPO pricing to market pricing. The market price after listing reflected secondary-market demand, not only the valuation at which shares were offered in the IPO.

This distinction matters because a stock that listed at a small premium can still re-rate after listing if market demand increases. At the same time, post-listing prices can move in either direction based on liquidity, results, sector sentiment and broader market conditions.

Why This Article Is More Than a Listing-Day Report

If this article had been published on March 24, the main story would have been the modest listing. But because the article date is April 1, the stronger story is the movement after listing.

The stock moved from a listing price of ₹328 on NSE to a close of ₹390.90 by April 1. It also moved from the BSE listing price of ₹332.30 to the same closing level. This shows that the major price action happened after the debut.

The post-listing rally also came despite a weak retail subscription during the IPO. That contrast makes GSP Crop Science a useful case for understanding why listing-day premium and post-listing price movement can be very different.

Key Risks from the Prospectus

GSP Crop Science operates in a regulated agrochemical business. The prospectus highlights several risk areas that remain relevant after listing.

• Product registration risk: Agrochemical products require approvals and registrations. Delay, non-renewal or cancellation of permits can affect operations.
• Regulatory risk: The company operates under laws related to insecticides, manufacturing, safety, environment and product approvals in India and overseas markets.
• Raw material risk: Agrochemical manufacturing depends on availability and pricing of chemicals, intermediates and other raw materials.
• Seasonality risk: Demand for crop protection products can be affected by cropping patterns, monsoon, pest incidence and agricultural cycles.
• International business risk: Export sales require compliance with foreign registrations, approvals and customer requirements.
• Debt and working capital risk: Part of the fresh issue proceeds is proposed to be used for repayment or prepayment of borrowings.
• Post-listing price risk: After listing, the stock price can change quickly based on market demand, liquidity, results, sector news and broader market movement.

Key Points

• GSP Crop Science listed on March 24, 2026.
• The IPO issue price was ₹320 per share.
• The stock listed at ₹332.30 on BSE and ₹328 on NSE.
• By April 1, 2026, the stock closed at ₹390.90.
• The April 1 closing price was about 22.16% above the IPO issue price.
• The stock touched an intraday high of ₹399.80 on April 1.
• At the April 1 high, the stock was about 24.94% above the IPO issue price.
• The IPO size was ₹400 crore, including a ₹240 crore fresh issue and ₹160 crore OFS.
• The lot size was 46 shares.
• The IPO was subscribed around 1.61 times overall.
• QIB and NII demand was stronger than retail demand.
• The company operates in agrochemicals through formulations and technicals.
• The prospectus shows 524 product registrations as of September 30, 2025.
• Fresh issue proceeds are mainly proposed for debt repayment or prepayment and general corporate purposes.

Source and Data Note

This article is based on GSP Crop Science Limited’s Prospectus dated March 18, 2026, listing-day information available for March 24, 2026, and historical share price data available for April 1, 2026. Listing prices and post-listing prices may vary by exchange and reporting source.

Disclaimer

This article is for informational and educational purposes only. It is not investment advice, a recommendation to buy, sell, hold or apply for any security, or a prediction of future stock performance. IPO and listed equity investments are subject to market risk, valuation risk, liquidity risk, business risk and regulatory risk. Readers should refer to the official prospectus, exchange filings and latest market data before making any investment decision.